Skip to main content
SpringerLink
Log in

Azoles

  • Chapter
  • First Online:
Aspergillosis: From Diagnosis to Prevention

  • 1527 Accesses

Abstract

The treatment of invasive aspergillosis remains difficult and until recently only polyenes and itraconazole were viable treatment options. However the development of newer triazoles (voriconazole, posaconazole) has been a welcome addition to the antifungal armamentarium. The proven efficacy of prophylactic posaconazole in high-risk patients, and the use of voriconazole during treatment of invasive aspergillosis have largely replaced amphotericin B and itraconazole use for these indications. Other extended-spectrum triazoles in preclinical development (ravuconazole, isavuconazole, and albaconazole) offer additional pharmacodynamic/pharmacokinetic advantages and will also be reviewed.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 259.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 329.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 329.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Dodds Ashley, E. S., Russell, L., Lewis J. S., Martin, C. & Andes, D. (2006) Pharmacology of systemic antifungal agents. Clin Infect Dis, 43, S28–39.

    Article  CAS  Google Scholar 

  2. Walsh, T. J., Anaissie, E. J., Denning, D. W., Herbrecht, R., Kontoyiannis, D. P., Marr, K. A., Morrison, V. A., Segal, B. H., Steinbach, W. J., Stevens, D. A., Van Burik, J. A., Wingard, J. R. & Patterson, T. F. (2008) Treatment of aspergillosis: clinical practice guidelines of the infectious diseases society of America. Clin Infect Dis, 46, 327–60.

    Article  CAS  PubMed  Google Scholar 

  3. Pasqualotto, A. C. & Denning, D. W. (2008) New and emerging treatments for fungal infections. J Antimicrob Chemother, 61 (Suppl 1), i19–30.

    Article  CAS  PubMed  Google Scholar 

  4. Ben-Ami, R., Lewis, R. E. & Kontoyiannis, D. P. (2008) Immunocompromised hosts: immunopharmacology of modern antifungals. Clin Infect Dis, 47, 226–35.

    Article  CAS  PubMed  Google Scholar 

  5. Shimokawa, O. & Nakayama, H. (1992) Increased sensitivity of Candida albicans cells accumulating 14 alpha-methylated sterols to active oxygen: possible relevance to in vivo efficacies of azole antifungal agents. Antimicrob Agents Chemother, 36, 1626–9.

    CAS  PubMed  Google Scholar 

  6. Slaven, J. W., Anderson, M. J., Sanglard, D., Dixon, G. K., Bille, J., Roberts, I. S. & Denning, D. W. (2002) Increased expression of a novel Aspergillus fumigatus ABC transporter gene, atrF, in the presence of itraconazole in an itraconazole resistant clinical isolate. Fungal Genet Biol, 36, 199–206.

    Article  CAS  PubMed  Google Scholar 

  7. Mann, P. A., Parmegiani, R. M., Wei, S. Q., Mendrick, C. A., Li, X., Loebenberg, D., Didomenico, B., Hare, R. S., Walker, S. S. & Mcnicholas, P. M. (2003) Mutations in Aspergillus fumigatus resulting in reduced susceptibility to posaconazole appear to be restricted to a single amino acid in the cytochrome P450 14alpha-demethylase. Antimicrob Agents Chemother, 47, 577–81.

    Article  CAS  PubMed  Google Scholar 

  8. Mellado, E., Garcia-Effron, G., Alcazar-Fuoli, L., Cuenca-Estrella, M. & Rodriguez-Tudela, J. L. (2004) Substitutions at methionine 220 in the 14alpha-sterol demethylase (Cyp51A) of Aspergillus fumigatus are responsible for resistance in vitro to azole antifungal drugs. Antimicrob Agents Chemother, 48, 2747–50.

    Article  CAS  PubMed  Google Scholar 

  9. Mellado, E., Garcia-Effron, G., Alcazar-Fuoli, L., Melchers, W. J., Verweij, P. E., Cuenca-Estrella, M. & Rodriguez-Tudela, J. L. (2007) A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations. Antimicrob Agents Chemother, 51, 1897–904.

    Article  CAS  PubMed  Google Scholar 

  10. Pfaller, M. A., Messer, S. A., Boyken, L., Rice, C., Tendolkar, S., Hollis, R. J. & Diekema, D. J. (2008) In vitro survey of triazole cross-resistance among more than 700 clinical isolates of Aspergillus species. J Clin Microbiol, 46, 2568–72.

    Article  CAS  PubMed  Google Scholar 

  11. Verweij, P. E., Mellado, E. & Melchers, W. J. (2007) Multiple-triazole-resistant aspergillosis. N Engl J Med, 356, 1481–3.

    Article  CAS  PubMed  Google Scholar 

  12. Howard, S. J., Cerar, D., Anderson, M., Albarrag, A., Fisher, M., Pasqualotto, A. C., Laverdiere, M., Arendrup, M. C., Perlin, D. & Denning, D. W. (2009) Emergence of azole resistance in Aspergillus fumigatus. Emerg Infect Dis, 15, 1068–76.

    Google Scholar 

  13. Manavathu, E. K., Cutright, J. L. & Chandrasekar, P. H. (1998) Organism-dependent fungicidal activities of azoles. Antimicrob Agents Chemother, 42, 3018–21.

    CAS  PubMed  Google Scholar 

  14. Groll, A. H., Piscitelli, S. C. & Walsh, T. J. (2001) Antifungal pharmacodynamics: concentration-effect relationships in vitro and in vivo. Pharmacotherapy, 21, 133S–48.

    Article  CAS  PubMed  Google Scholar 

  15. Kintzel, P. E., Rollins, C. J., Yee, W. J. & List, A. F. (1995) Low itraconazole serum concentrations following administration of itraconazole suspension to critically ill allogeneic bone marrow transplant recipients. Ann Pharmacother, 29, 140–3.

    CAS  PubMed  Google Scholar 

  16. Boogaerts, M. A., Verhoef, G. E., Zachee, P., Demuynck, H., Verbist, L. & De Beule, K. (1989) Antifungal prophylaxis with itraconazole in prolonged neutropenia: correlation with plasma levels. Mycoses, 32 (Suppl 1), 103–8.

    PubMed  Google Scholar 

  17. Pasqualotto, A. C. & Denning, D. W. (2007) Generic substitution of itraconazole resulting in sub-therapeutic levels and resistance. Int J Antimicrob Agents, 30, 93–4.

    Article  CAS  PubMed  Google Scholar 

  18. Jaruratanasirikul, S. & Kleepkaew, A. (1997) Influence of an acidic beverage (Coca-Cola) on the absorption of itraconazole. Eur J Clin Pharmacol, 52, 235–7.

    Article  CAS  PubMed  Google Scholar 

  19. Lange, D., Pavao, J. H., Wu, J. & Klausner, M. (1997) Effect of a cola beverage on the bioavailability of itraconazole in the presence of H2 blockers. J Clin Pharmacol, 37, 535–40.

    CAS  PubMed  Google Scholar 

  20. Barone, J. A., Moskovitz, B. L., Guarnieri, J., Hassell, A. E., Colaizzi, J. L., Bierman, R. H. & Jessen, L. (1998) Enhanced bioavailability of itraconazole in hydroxypropyl-beta-cyclodextrin solution versus capsules in healthy volunteers. Antimicrob Agents Chemother, 42, 1862–5.

    CAS  PubMed  Google Scholar 

  21. Van De Velde, V. J., Van Peer, A. P., Heykants, J. J., Woestenborghs, R. J., Van Rooy, P., De Beule, K. L. & Cauwenbergh, G. F. (1996) Effect of food on the pharmacokinetics of a new hydroxypropyl-beta-cyclodextrin formulation of itraconazole. Pharmacotherapy, 16, 424–8.

    PubMed  Google Scholar 

  22. Stevens, D. A. (1999) Itraconazole in cyclodextrin solution. Pharmacotherapy, 19, 603–11.

    Article  CAS  PubMed  Google Scholar 

  23. Como, J. A. & Dismukes, W. E. (1994) Oral azole drugs as systemic antifungal therapy. N Engl J Med, 330, 263–72.

    Article  CAS  PubMed  Google Scholar 

  24. Prentice, A. G., Warnock, D. W., Johnson, S. A., Phillips, M. J. & Oliver, D. A. (1994) Multiple dose pharmacokinetics of an oral solution of itraconazole in autologous bone marrow transplant recipients. J Antimicrob Chemother, 34, 247–52.

    Article  CAS  PubMed  Google Scholar 

  25. Grant, S. M. & Clissold, S. P. (1989) Itraconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses. Drugs, 37, 310–44.

    Article  CAS  PubMed  Google Scholar 

  26. Van Cauteren, H., Heykants, J., De Coster, R. & Cauwenbergh, G. (1987) Itraconazole: pharmacologic studies in animals and humans. Rev Infect Dis, 9 (Suppl 1), S43–6.

    PubMed  Google Scholar 

  27. Miyama, T., Takanaga, H., Matsuo, H., Yamano, K., Yamamoto, K., Iga, T., Naito, M., Tsuruo, T., Ishizuka, H., Kawahara, Y. & Sawada, Y. (1998) P-glycoprotein-mediated transport of itraconazole across the blood-brain barrier. Antimicrob Agents Chemother, 42, 1738–44.

    CAS  PubMed  Google Scholar 

  28. Warnock, D. W., Turner, A. & Burke, J. (1988) Comparison of high performance liquid chromatographic and microbiological methods for determination of itraconazole. J Antimicrob Chemother, 21, 93–100.

    Article  CAS  PubMed  Google Scholar 

  29. Groll, A. H., Wood, L., Roden, M., Mickiene, D., Chiou, C. C., Townley, E., Dad, L., Piscitelli, S. C. & Walsh, T. J. (2002) Safety, pharmacokinetics, and pharmacodynamics of cyclodextrin itraconazole in pediatric patients with oropharyngeal candidiasis. Antimicrob Agents Chemother, 46, 2554–63.

    Article  CAS  PubMed  Google Scholar 

  30. De Beule, K. & Van Gestel, J. (2001) Pharmacology of itraconazole. Drugs, 61 (Suppl 1), 27–37.

    Article  PubMed  Google Scholar 

  31. Itraconazole [package insert] (2003) (Sempera) product monograph. Janssen-Cilag GmbH, N., Germany.

    Google Scholar 

  32. Tucker, R. M., Haq, Y., Denning, D. W. & Stevens, D. A. (1990) Adverse events associated with itraconazole in 189 patients on chronic therapy. J Antimicrob Chemother, 26, 561–6.

    Article  CAS  PubMed  Google Scholar 

  33. Sharkey, P. K., Rinaldi, M. G., Dunn, J. F., Hardin, T. C., Fetchick, R. J. & Graybill, J. R. (1991) High-dose itraconazole in the treatment of severe mycoses. Antimicrob Agents Chemother, 35, 707–13.

    CAS  PubMed  Google Scholar 

  34. Glasmacher, A., Hahn, C., Molitor, E., Marklein, G., Sauerbruch, T. & Schmidt-Wolf, I. G. (1999) Itraconazole through concentrations in antifungal prophylaxis with six different dosing regimens using hydroxypropyl-beta-cyclodextrin oral solution or coated-pellet capsules. Mycoses, 42, 591–600.

    Article  CAS  PubMed  Google Scholar 

  35. Foot, A. B., Veys, P. A. & Gibson, B. E. (1999) Itraconazole oral solution as antifungal prophylaxis in children undergoing stem cell transplantation or intensive chemotherapy for haematological disorders. Bone Marrow Transplant, 24, 1089–93.

    Article  CAS  PubMed  Google Scholar 

  36. Lavrijsen, A. P., Balmus, K. J., Nugteren-Huying, W. M., Roldaan, A. C., Van't Wout, J. W. & Stricker, B. H. (1992) Hepatic injury associated with itraconazole. Lancet, 340, 251–2.

    Article  CAS  PubMed  Google Scholar 

  37. Ahmad, S. R., Singer, S. J. & Leissa, B. G. (2001) Congestive heart failure associated with itraconazole. Lancet, 357, 1766–7.

    Article  CAS  PubMed  Google Scholar 

  38. Neuvonen, P. J. & Jalava, K. M. (1996) Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther, 60, 54–61.

    Article  CAS  PubMed  Google Scholar 

  39. Kantola, T., Kivisto, K. T. & Neuvonen, P. J. (1998) Effect of itraconazole on the pharmacokinetics of atorvastatin. Clin Pharmacol Ther, 64, 58–65.

    Article  CAS  PubMed  Google Scholar 

  40. Neuvonen, P. J., Kantola, T. & Kivisto, K. T. (1998) Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin Pharmacol Ther, 63, 332–41.

    Article  CAS  PubMed  Google Scholar 

  41. Lees, R. S. & Lees, A. M. (1995) Rhabdomyolysis from the co administration of lovastatin and the antifungal agent itraconazole. N Engl J Med, 333, 664–5.

    Article  CAS  PubMed  Google Scholar 

  42. Varhe, A., Olkkola, K. T. & Neuvonen, P. J. (1994) Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther, 56, 601–7.

    Article  CAS  PubMed  Google Scholar 

  43. Ahonen, J., Olkkola, K. T. & Neuvonen, P. J. (1995) Effect of itraconazole and terbinafine on the pharmacokinetics and pharmacodynamics of midazolam in healthy volunteers. Br J Clin Pharmacol, 40, 270–2.

    CAS  PubMed  Google Scholar 

  44. Ahonen, J., Olkkola, K. T. & Neuvonen, P. J. (1996) Lack of effect of antimycotic itraconazole on the pharmacokinetics or pharmacodynamics of temazepam. Ther Drug Monit, 18, 124–7.

    Article  CAS  PubMed  Google Scholar 

  45. Kramer, M. R., Marshall, S. E., Denning, D. W., Keogh, A. M., Tucker, R. M., Galgiani, J. N., Lewiston, N. J., Stevens, D. A. & Theodore, J. (1990) Cyclosporine and itraconazole interaction in heart and lung transplant recipients. Ann Intern Med, 113, 327–9.

    CAS  PubMed  Google Scholar 

  46. Varis, T., Kaukonen, K. M., Kivisto, K. T. & Neuvonen, P. J. (1998) Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole. Clin Pharmacol Ther, 64, 363–8.

    Article  CAS  PubMed  Google Scholar 

  47. Tucker, R. M., Denning, D. W., Hanson, L. H., Rinaldi, M. G., Graybill, J. R., Sharkey, P. K., Pappagianis, D. & Stevens, D. A. (1992) Interaction of azoles with rifampin, phenytoin, and carbamazepine: in vitro and clinical observations. Clin Infect Dis, 14, 165–74.

    CAS  PubMed  Google Scholar 

  48. Kivisto, K. T., Lamberg, T. S., Kantola, T. & Neuvonen, P. J. (1997) Plasma buspirone concentrations are greatly increased by erythromycin and itraconazole. Clin Pharmacol Ther, 62, 348–54.

    Article  CAS  PubMed  Google Scholar 

  49. Engels, F. K., Ten Tije, A. J., Baker, S. D., Lee, C. K., Loos, W. J., Vulto, A. G., Verweij, J. & Sparreboom, A. (2004) Effect of cytochrome P450 3A4 inhibition on the pharmacokinetics of docetaxel. Clin Pharmacol Ther, 75, 448–54.

    Article  CAS  PubMed  Google Scholar 

  50. Grub, S., Bryson, H., Goggin, T., Ludin, E. & Jorga, K. (2001) The interaction of saquinavir (soft gelatin capsule) with ketoconazole, erythromycin and rifampicin: comparison of the effect in healthy volunteers and in HIV-infected patients. Eur J Clin Pharmacol, 57, 115–21.

    Article  CAS  PubMed  Google Scholar 

  51. Jeng, M. R. & Feusner, J. (2001) Itraconazole-enhanced vincristine neurotoxicity in a child with acute lymphoblastic leukemia. Pediatr Hematol Oncol, 18, 137–42.

    Article  CAS  PubMed  Google Scholar 

  52. Kaukonen, K. M., Olkkola, K. T. & Neuvonen, P. J. (1997) Itraconazole increases plasma concentrations of quinidine. Clin Pharmacol Ther, 62, 510–7.

    Article  CAS  PubMed  Google Scholar 

  53. Lefebvre, R. A., Van Peer, A. & Woestenborghs, R. (1997) Influence of itraconazole on the pharmacokinetics and electrocardiographic effects of astemizole. Br J Clin Pharmacol, 43, 319–22.

    Article  CAS  PubMed  Google Scholar 

  54. Honig, P. K., Wortham, D. C., Hull, R., Zamani, K., Smith, J. E. & Cantilena, L. R. (1993) Itraconazole affects single-dose terfenadine pharmacokinetics and cardiac repolarization pharmacodynamics. J Clin Pharmacol, 33, 1201–6.

    CAS  PubMed  Google Scholar 

  55. Piscitelli, S. C., Flexner, C., Minor, J. R., Polis, M. A. & Masur, H. (1996) Drug interactions in patients infected with human immunodeficiency virus. Clin Infect Dis, 23, 685–93.

    CAS  PubMed  Google Scholar 

  56. Groll, A. H., Gea-Banacloche, J. C., Glasmacher, A., Just-Nuebling, G., Maschmeyer, G. & Walsh, T. J. (2003) Clinical pharmacology of antifungal compounds. Infect Dis Clin North Am, 17, 159–91, ix.

    Article  PubMed  Google Scholar 

  57. Denning, D. W., Lee, J. Y., Hostetler, J. S., Pappas, P., Kauffman, C. A., Dewsnup, D. H., Galgiani, J. N., Graybill, J. R., Sugar, A. M., Catanzaro, A. et al. (1994) NIAID mycoses study group multicenter trial of oral itraconazole therapy for invasive aspergillosis. Am J Med, 97, 135–44.

    Article  CAS  PubMed  Google Scholar 

  58. Caillot, D., Bassaris, H., Mcgeer, A., Arthur, C., Prentice, H. G., Seifert, W. & De Beule, K. (2001) Intravenous itraconazole followed by oral itraconazole in the treatment of invasive pulmonary aspergillosis in patients with hematologic malignancies, chronic granulomatous disease, or AIDS. Clin Infect Dis, 33, e83–90.

    Article  CAS  PubMed  Google Scholar 

  59. Boogaerts, M., Winston, D. J., Bow, E. J., Garber, G., Reboli, A. C., Schwarer, A. P., Novitzky, N., Boehme, A., Chwetzoff, E. & De Beule, K. (2001) Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlled trial. Ann Intern Med, 135, 412–22.

    CAS  PubMed  Google Scholar 

  60. Hughes, W. T., Armstrong, D., Bodey, G. P., Bow, E. J., Brown, A. E., Calandra, T., Feld, R., Pizzo, P. A., Rolston, K. V., Shenep, J. L. & Young, L. S. (2002) 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis, 34, 730–51.

    Article  PubMed  Google Scholar 

  61. Vardakas, K. Z., Michalopoulos, A. & Falagas, M. E. (2005) Fluconazole versus itraconazole for antifungal prophylaxis in neutropenic patients with haematological malignancies: a meta-analysis of randomised-controlled trials. Br J Haematol, 131, 22–8.

    Article  CAS  PubMed  Google Scholar 

  62. Manavathu, E. K., Cutright, J. L., Loebenberg, D. & Chandrasekar, P. H. (2000) A comparative study of the in vitro susceptibilities of clinical and laboratory-selected resistant isolates of Aspergillus spp. to amphotericin B, itraconazole, voriconazole and posaconazole (SCH 56592). J Antimicrob Chemother, 46, 229–34.

    Article  CAS  PubMed  Google Scholar 

  63. Groll, A. H. & Walsh, T. J. (2005) Posaconazole: clinical pharmacology and potential for management of fungal infections. Expert Rev Anti Infect Ther, 3, 467–87.

    Article  CAS  PubMed  Google Scholar 

  64. Nagappan, V. & Deresinski, S. (2007) Reviews of anti-infective agents: posaconazole: a broad-spectrum triazole antifungal agent. Clin Infect Dis, 45, 1610–7.

    Article  CAS  PubMed  Google Scholar 

  65. Andes, D., Marchillo, K., Conklin, R., Krishna, G., Ezzet, F., Cacciapuoti, A. & Loebenberg, D. (2004) Pharmacodynamics of a new triazole, posaconazole, in a murine model of disseminated candidiasis. Antimicrob Agents Chemother, 48, 137–42.

    Article  CAS  PubMed  Google Scholar 

  66. Courtney, R., Wexler, D., Radwanski, E., Lim, J. & Laughlin, M. (2004) Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults. Br J Clin Pharmacol, 57, 218–22.

    Article  PubMed  Google Scholar 

  67. Ezzet, F., Wexler, D., Courtney, R., Krishna, G., Lim, J. & Laughlin, M. (2005) Oral bioavailability of posaconazole in fasted healthy subjects: comparison between three regimens and basis for clinical dosage recommendations. Clin Pharmacokinet, 44, 211–20.

    Article  CAS  PubMed  Google Scholar 

  68. Courtney, R., Radwanski, E., Lim, J. & Laughlin, M. (2004) Pharmacokinetics of posaconazole coadministered with antacid in fasting or nonfasting healthy men. Antimicrob Agents Chemother, 48, 804–8.

    Article  CAS  PubMed  Google Scholar 

  69. Jain, R. & Pottinger, P. (2008) The effect of gastric acid on the absorption of posaconazole. Clin Infect Dis, 46, 1627; author reply -8.

    Article  PubMed  Google Scholar 

  70. Posaconazole [package insert]. Kenilworth, NJ: Schering Corporation, 2006.

    Google Scholar 

  71. Krishna, G., Ma L., Malavade, D., Medlock, M., Mcleod, J. 2008 Effect of gastric pH, dosing regimen and prandial state, food and meal timing relative to dose, and gastrointestinal motility on absorption and pharmacokinetics of the antifungal posaconazole. In: 18th European Congress of Clinical Microbiology and Infectious Diseases & Barcelona, S., P1264.

    Google Scholar 

  72. Courtney, R., Pai, S., Laughlin, M., Lim, J. & Batra, V. (2003) Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults. Antimicrob Agents Chemother, 47, 2788–95.

    Article  CAS  PubMed  Google Scholar 

  73. Krishna, G., Sansone-Parsons, A., Martinho, M., Kantesaria, B. & Pedicone, L. (2007) Posaconazole plasma concentrations in juvenile patients with invasive fungal infection. Antimicrob Agents Chemother, 51, 812–8.

    Article  CAS  PubMed  Google Scholar 

  74. Sansone-Parsons, A., Krishna, G., Calzetta, A., Wexler, D., Kantesaria, B., Rosenberg, M. A. & Saltzman, M. A. (2006) Effect of a nutritional supplement on posaconazole pharmacokinetics following oral administration to healthy volunteers. Antimicrob Agents Chemother, 50, 1881–3.

    Article  CAS  PubMed  Google Scholar 

  75. Meletiadis, J., Chanock, S. & Walsh, T. J. (2006) Human pharmacogenomic variations and their implications for antifungal efficacy. Clin Microbiol Rev, 19, 763–87.

    Article  CAS  PubMed  Google Scholar 

  76. Courtney, R., Sansone, A., Smith, W., Marbury, T., Statkevich, P., Martinho, M., Laughlin, M. & Swan, S. (2005) Posaconazole pharmacokinetics, safety, and tolerability in subjects with varying degrees of chronic renal disease. J Clin Pharmacol, 45, 185–92.

    Article  CAS  PubMed  Google Scholar 

  77. Ullmann, A. J., Lipton, J. H., Vesole, D. H., Chandrasekar, P., Langston, A., Tarantolo, S. R., Greinix, H., Morais De Azevedo, W., Reddy, V., Boparai, N., Pedicone, L., Patino, H. & Durrant, S. (2007) Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med, 356, 335–47.

    Article  CAS  PubMed  Google Scholar 

  78. Cornely, O. A., Maertens, J., Winston, D. J., Perfect, J., Ullmann, A. J., Walsh, T. J., Helfgott, D., Holowiecki, J., Stockelberg, D., Goh, Y. T., Petrini, M., Hardalo, C., Suresh, R. & Angulo-Gonzalez, D. (2007) Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med, 356, 348–59.

    Article  CAS  PubMed  Google Scholar 

  79. Graybill, J. R., II, Bustamante, A. B., Cornely, O. A., Gaona-Flores, V., Afif, C., Graham, D. R., Greenberg, R. N., Hadley, S., Langston, A., Negroni, R., Perfect, J. R., Pitisuttithum, P., Restrepo, A., Schiller, G., Pedicone, L. & Ullmann, A. J. (2006) Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections. Clin Infect Dis, 42, 1726–34.

    Article  PubMed  Google Scholar 

  80. Purkins, L., Wood, N., Ghahramani, P., Love, E. R., Eve, M. D. & Fielding, A. (2003) Coadministration of voriconazole and phenytoin: pharmacokinetic interaction, safety, and toleration. Br J Clin Pharmacol, 56 (Suppl 1), 37–44.

    Article  CAS  PubMed  Google Scholar 

  81. Kirkpatrick, W. R., Mcatee, R. K., Fothergill, A. W., Loebenberg, D., Rinaldi, M. G. & Patterson, T. F. (2000) Efficacy of SCH56592 in a rabbit model of invasive aspergillosis. Antimicrob Agents Chemother, 44, 780–2.

    Article  CAS  PubMed  Google Scholar 

  82. Petraitiene, R., Petraitis, V., Groll, A. H., Sein, T., Piscitelli, S., Candelario, M., Field-Ridley, A., Avila, N., Bacher, J. & Walsh, T. J. (2001) Antifungal activity and pharmacokinetics of posaconazole (SCH 56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: correlation with galactomannan antigenemia. Antimicrob Agents Chemother, 45, 857–69.

    Article  CAS  PubMed  Google Scholar 

  83. Walsh, T. J., Raad, I., Patterson, T. F., Chandrasekar, P., Donowitz, G. R., Graybill, R., Greene, R. E., Hachem, R., Hadley, S., Herbrecht, R., Langston, A., Louie, A., Ribaud, P., Segal, B. H., Stevens, D. A., Van Burik, J. A., White, C. S., Corcoran, G., Gogate, J., Krishna, G., Pedicone, L., Hardalo, C. & Perfect, J. R. (2007) Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis, 44, 2–12.

    Article  CAS  PubMed  Google Scholar 

  84. Johnson, L. B. & Kauffman, C. A. (2003) Voriconazole: a new triazole antifungal agent. Clin Infect Dis, 36, 630–7.

    Article  CAS  PubMed  Google Scholar 

  85. Clancy, C. J. & Nguyen, M. H. (1998) In vitro efficacy and fungicidal activity of voriconazole against Aspergillus and Fusarium species. Eur J Clin Microbiol Infect Dis, 17, 573–5.

    CAS  PubMed  Google Scholar 

  86. Espinel-Ingroff, A. (2001) In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi. J Clin Microbiol, 39, 954–8.

    Article  CAS  PubMed  Google Scholar 

  87. Purkins, L., Wood, N., Ghahramani, P., Greenhalgh, K., Allen, M. J. & Kleinermans, D. (2002) Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens. Antimicrob Agents Chemother, 46, 2546–53.

    Article  CAS  PubMed  Google Scholar 

  88. Lazarus, H. M., Blumer, J. L., Yanovich, S., Schlamm, H. & Romero, A. (2002) Safety and pharmacokinetics of oral voriconazole in patients at risk of fungal infection: a dose escalation study. J Clin Pharmacol, 42, 395–402.

    Article  CAS  PubMed  Google Scholar 

  89. Ikeda, Y., Umemura, K., Kondo, K., Sekiguchi, K., Miyoshi, S. & Nakashima, M. (2004) Pharmacokinetics of voriconazole and cytochrome P450 2C19 genetic status. Clin Pharmacol Ther, 75, 587–8.

    Article  CAS  PubMed  Google Scholar 

  90. Pasqualotto, A. C., Shah, M., Wynn, R. & Denning, D. W. (2008) Voriconazole plasma monitoring. Arch Dis Child, 93, 578–81.

    Article  CAS  PubMed  Google Scholar 

  91. Voriconazole (V-fend) Summary of product characteristics, Pfizer Ltd.

    Google Scholar 

  92. Ally, R., Schurmann, D., Kreisel, W., Carosi, G., Aguirrebengoa, K., Dupont, B., Hodges, M., Troke, P. & Romero, A. J. (2001) A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. Clin Infect Dis, 33, 1447–54.

    Article  CAS  PubMed  Google Scholar 

  93. Walsh, T. J., Pappas, P., Winston, D. J., Lazarus, H. M., Petersen, F., Raffalli, J., Yanovich, S., Stiff, P., Greenberg, R., Donowitz, G., Schuster, M., Reboli, A., Wingard, J., Arndt, C., Reinhardt, J., Hadley, S., Finberg, R., Laverdiere, M., Perfect, J., Garber, G., Fioritoni, G., Anaissie, E. & Lee, J. (2002) Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med, 346, 225–34.

    Article  CAS  PubMed  Google Scholar 

  94. Denning, D. W., Ribaud, P., Milpied, N., Caillot, D., Herbrecht, R., Thiel, E., Haas, A., Ruhnke, M. & Lode, H. (2002) Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis, 34, 563–71.

    Article  CAS  PubMed  Google Scholar 

  95. Jain, L. R. & Denning, D. W. (2006) The efficacy and tolerability of voriconazole in the treatment of chronic cavitary pulmonary aspergillosis. J Infect, 52, e133–7.

    Article  PubMed  Google Scholar 

  96. Mccarthy, K. L., Playford, E. G., Looke, D. F. & Whitby, M. (2007) Severe photosensitivity causing multifocal squamous cell carcinomas secondary to prolonged voriconazole therapy. Clin Infect Dis, 44, e55–6.

    Article  CAS  PubMed  Google Scholar 

  97. Brunel, A. S., Fraisse, T., Lechiche, C., Pinzani, V., Mauboussin, J. M. & Sotto, A. (2008) Multifocal squamous cell carcinomas in an HIV-infected patient with a long-term voriconazole therapy. AIDS, 22, 905–6.

    Article  PubMed  Google Scholar 

  98. Scherpbier, H. J., Hilhorst, M. I. & Kuijpers, T. W. (2003) Liver failure in a child receiving highly active antiretroviral therapy and voriconazole. Clin Infect Dis, 37, 828–30.

    Article  PubMed  Google Scholar 

  99. Philips, J. A., Marty, F. M., Stone, R. M., Koplan, B. A., Katz, J. T. & Baden, L. R. (2007) Torsades de pointes associated with voriconazole use. Transpl Infect Dis, 9, 33–6.

    Article  CAS  PubMed  Google Scholar 

  100. Pascual, A., Calandra, T., Bolay, S., Buclin, T., Bille, J. & Marchetti, O. (2008) Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis, 46, 201–11.

    Article  CAS  PubMed  Google Scholar 

  101. Lewis, R. E. (2008) What is the "therapeutic range" for voriconazole? Clin Infect Dis, 46, 212–4.

    Article  CAS  PubMed  Google Scholar 

  102. Zonios, D. I., Gea-Banacloche, J., Childs, R. & Bennett, J. E. (2008) Hallucinations during voriconazole therapy. Clin Infect Dis, 47, e7–10.

    Article  CAS  PubMed  Google Scholar 

  103. Pai, M. P. & Allen, S. (2003) Voriconazole inhibition of tacrolimus metabolism. Clin Infect Dis, 36, 1089–91.

    Article  PubMed  Google Scholar 

  104. Romero, A. J., Le Pogamp, P., Nilsson, L. G. & Wood, N. (2002) Effect of voriconazole on the pharmacokinetics of cyclosporine in renal transplant patients. Clin Pharmacol Ther, 71, 226–34.

    Article  CAS  PubMed  Google Scholar 

  105. Olkkola, K. T., Backman, J. T. & Neuvonen, P. J. (1994) Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther, 55, 481–5.

    Article  CAS  PubMed  Google Scholar 

  106. Liu, P., Foster, G., Gandelman, K., Labadie, R. R., Allison, M. J., Gutierrez, M. J. & Sharma, A. (2007) Steady-state pharmacokinetic and safety profiles of voriconazole and ritonavir in healthy male subjects. Antimicrob Agents Chemother, 51, 3617–26.

    Article  CAS  PubMed  Google Scholar 

  107. Liu, P., Foster, G., Labadie, R. R., Gutierrez, M. J. & Sharma, A. (2008) Pharmacokinetic interaction between voriconazole and efavirenz at steady state in healthy male subjects. J Clin Pharmacol, 48, 73–84.

    Article  CAS  PubMed  Google Scholar 

  108. Liu, P., Foster, G., Labadie, R., Somoza, E. & Sharma, A. (2007) Pharmacokinetic interaction between voriconazole and methadone at steady state in patients on methadone therapy. Antimicrob Agents Chemother, 51, 110–8.

    Article  CAS  PubMed  Google Scholar 

  109. Purkins, L., Wood, N., Kleinermans, D. & Nichols, D. (2003) Voriconazole potentiates warfarin-induced prothrombin time prolongation. Br J Clin Pharmacol, 56 (Suppl 1), 24–9.

    Article  CAS  PubMed  Google Scholar 

  110. Gerzenshtein, L., Patel, S. M., Scarsi, K. K., Postelnick, M. J. & Flaherty, J. P. (2005) Breakthrough Candida infections in patients receiving voriconazole. Ann Pharmacother, 39, 1342–5.

    Article  PubMed  Google Scholar 

  111. Geist, M. J., Egerer, G., Burhenne, J., Riedel, K. D. & Mikus, G. (2007) Induction of voriconazole metabolism by rifampin in a patient with acute myeloid leukemia: importance of interdisciplinary communication to prevent treatment errors with complex medications. Antimicrob Agents Chemother, 51, 3455–6.

    Article  CAS  PubMed  Google Scholar 

  112. Herbrecht, R., Denning, D. W., Patterson, T. F., Bennett, J. E., Greene, R. E., Oestmann, J. W., Kern, W. V., Marr, K. A., Ribaud, P., Lortholary, O., Sylvester, R., Rubin, R. H., Wingard, J. R., Stark, P., Durand, C., Caillot, D., Thiel, E., Chandrasekar, P. H., Hodges, M. R., Schlamm, H. T., Troke, P. F. & De Pauw, B. (2002) Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med, 347, 408–15.

    Article  CAS  PubMed  Google Scholar 

  113. Schwartz, S., Ruhnke, M., Ribaud, P., Corey, L., Driscoll, T., Cornely, O. A., Schuler, U., Lutsar, I., Troke, P. & Thiel, E. (2005) Improved outcome in central nervous system aspergillosis, using voriconazole treatment. Blood, 106, 2641–5.

    Article  CAS  PubMed  Google Scholar 

  114. Mouas, H., Lutsar, I., Dupont, B., Fain, O., Herbrecht, R., Lescure, F. X. & Lortholary, O. (2005) Voriconazole for invasive bone aspergillosis: a worldwide experience of 20 cases. Clin Infect Dis, 40, 1141–7.

    Article  CAS  PubMed  Google Scholar 

  115. Singh, N., Limaye, A. P., Forrest, G., Safdar, N., Munoz, P., Pursell, K., Houston, S., Rosso, F., Montoya, J. G., Patton, P., Del Busto, R., Aguado, J. M., Fisher, R. A., Klintmalm, G. B., Miller, R., Wagener, M. M., Lewis, R. E., Kontoyiannis, D. P. & Husain, S. (2006) Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study. Transplantation, 81, 320–6.

    Article  CAS  PubMed  Google Scholar 

  116. Marr, K. A., Boeckh, M., Carter, R. A., Kim, H. W. & Corey, L. (2004) Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis, 39, 797–802.

    Article  CAS  PubMed  Google Scholar 

  117. Espinel-Ingroff, A., Fothergill, A., Peter, J., Rinaldi, M. G. & Walsh, T. J. (2002) Testing conditions for determination of minimum fungicidal concentrations of new and established antifungal agents for Aspergillus spp.: NCCLS collaborative study. J Clin Microbiol, 40, 3204–8.

    Article  CAS  PubMed  Google Scholar 

  118. Moore, C. B., Walls, C. M. & Denning, D. W. (2000) In vitro activity of the new triazole BMS-207147 against Aspergillus species in comparison with itraconazole and amphotericin B. Antimicrob Agents Chemother, 44, 441–3.

    Article  CAS  PubMed  Google Scholar 

  119. Pfaller, M. A., Messer, S. A., Hollis, R. J. & Jones, R. N. (2002) Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000. Antimicrob Agents Chemother, 46, 1032–7.

    Article  CAS  PubMed  Google Scholar 

  120. Petraitiene, R., Petraitis, V., Lyman, C. A., Groll, A. H., Mickiene, D., Peter, J., Bacher, J., Roussillon, K., Hemmings, M., Armstrong, D., Avila, N. A. & Walsh, T. J. (2004) Efficacy, safety, and plasma pharmacokinetics of escalating dosages of intravenously administered ravuconazole lysine phosphoester for treatment of experimental pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob Agents Chemother, 48, 1188–96.

    Article  CAS  PubMed  Google Scholar 

  121. Yan, J. H., Marino, M. R., Smith, R. A., Kanamaluru, V., O'mara, E. M. & Grasela, D. M. (2006) The effect of ravuconazole on the pharmacokinetics of nelfinavir in healthy male volunteers. J Clin Pharmacol, 46, 193–200.

    Article  CAS  PubMed  Google Scholar 

  122. Marino, M. R., Mummaneni, V., Norton, J. et al. (2001) Ravuconazole exposure-response relationship in hiv-patients with oropharyngeal candidiasis. In: Abstracts of the Forty-First Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, Abstract J-1622. American Society for Microbiology, Washington, DC.

    Google Scholar 

  123. Olsen, S.J., Mummaneni, V., Rolan, P. et al. (2000) Ravuconazole single ascending oral dose study in healthy subjects. In: Abstracts of the Fortieth Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, Abstract a-838. American Society for Microbiology, Washington, DC

    Google Scholar 

  124. Gupta, A. K., Leonardi, C., Stoltz, R. R., Pierce, P. F. & Conetta, B. (2005) A phase I/II randomized, double-blind, placebo-controlled, dose-ranging study evaluating the efficacy, safety and pharmacokinetics of ravuconazole in the treatment of onychomycosis. J Eur Acad Dermatol Venereol, 19, 437–43.

    Article  CAS  PubMed  Google Scholar 

  125. Hata, K., Kimura, J., Miki, H., Toyosawa, T., Moriyama, M. & Katsu, K. (1996) Efficacy of ER-30346, a novel oral triazole antifungal agent, in experimental models of aspergillosis, candidiasis, and cryptococcosis. Antimicrob Agents Chemother, 40, 2243–7.

    CAS  PubMed  Google Scholar 

  126. Kirkpatrick, W. R., Perea, S., Coco, B. J. & Patterson, T. F. (2002) Efficacy of ravuconazole (BMS-207147) in a guinea pig model of disseminated aspergillosis. J Antimicrob Chemother, 49, 353–7.

    Article  CAS  PubMed  Google Scholar 

  127. Warn, P. A., Sharp, A. & Denning, D. W. (2006) In vitro activity of a new triazole BAL4815, the active component of BAL8557 (the water-soluble prodrug), against Aspergillus spp. J Antimicrob Chemother, 57, 135–8.

    Article  CAS  PubMed  Google Scholar 

  128. Schmitt-Hoffmann, A., Roos, B., Heep, M., Schleimer, M., Weidekamm, E., Brown, T., Roehrle, M. & Beglinger, C. (2006) Single-ascending-dose pharmacokinetics and safety of the novel broad-spectrum antifungal triazole BAL4815 after intravenous infusions (50, 100, and 200 milligrams) and oral administrations (100, 200, and 400 milligrams) of its prodrug, BAL8557, in healthy volunteers. Antimicrob Agents Chemother, 50, 279–85.

    Article  CAS  PubMed  Google Scholar 

  129. Schmitt-Hoffmann, A., Roos, B., Spickermann, J., Heep, M., Roehrl, M., Schoetzau, A. & Simmens, U. (2008) No Relevant Food Effect in Man on Isavuconazole Oral Pharmacokinetics Preliminary Data. In 48th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC.

    Google Scholar 

  130. Warn, P. A., Sharp, A., Mosquera, J., Spickermann, J., Schmitt-Hoffmann, A., Heep, M. & Denning, D. W. (2006) Comparative in vivo activity of BAL4815, the active component of the prodrug BAL8557, in a neutropenic murine model of disseminated Aspergillus flavus. J Antimicrob Chemother, 58, 1198–207.

    Article  CAS  PubMed  Google Scholar 

  131. Schmitt-Hoffmann, A., Ross, B., Spickermann, J., Heep, M., Peterfai, E. & Edwards, D. (2008) Pharmacokinetics of isavuconazole in liver impairment preliminary data. In 48th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC.

    Google Scholar 

  132. Viljoen, J. J., Mitha, I., Heep, M. et al. (2005) Efficacy, safety, and tolerability of three different dosing regimens of BAL8557 vs fluconazole in a double-blind randomized, multicenter trial for ther treatment of esophageal candidiasis in immunocompromised adults. In: Abstracts of the Forty-Fifth Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington DC, Abstracct LB2-32. American Society for Microbiology, Washington DC.

    Google Scholar 

  133. Schmitt-Hoffman A., Roos, B., Sauer, J. et al. (2005) Effect of rifampicin on the pharmacokinetics of BAL4815 at steady state after multiple oral doses of BAL8557 (WSA) and rifampicin. In: Abstracts of the Sixteenth Congress of the International Society for Human and Animal Mycology (ISHAM), Paris, France, P-0319.

    Google Scholar 

  134. Schmitt-Hoffman, A., Roos, B., Sauer, J. et al. (2006) Effect of BAL8557, a water-soluble azole pro-drug (WSA), on the pharmacokinetics of S- and R-warfarin. In: Abstracts of the Sixteenth Congress of the International Society for Human and Animal Mycology (ISHAM), Paris, France, P-0321.

    Google Scholar 

  135. Schmitt-Hoffman, A., Roos, B., Sauer, J. et al. (2006) Effect of BAL8557, a water-soluble azole pro-drug (WSA), on the pharmacokinetics of ciclosporin. In: Abstracts of the Sixteenth Congress of the International Society for Human and Animal Mycology (ISHAM), Paris, France, P-0136.

    Google Scholar 

  136. Capilla, J., Ortoneda, M., Pastor, F. J. & Guarro, J. (2001) In vitro antifungal activities of the new triazole UR-9825 against clinically important filamentous fungi. Antimicrob Agents Chemother, 45, 2635–7.

    Article  CAS  PubMed  Google Scholar 

  137. Bartroli, J., Turmo, E., Alguero, M., Boncompte, E., Vericat, M. L., Conte, L., Ramis, J., Merlos, M., Garcia-Rafanell, J. & Forn, J. (1998) New azole antifungals. 3. Synthesis and antifungal activity of 3-substituted-4(3H)-quinazolinones. J Med Chem, 41, 1869–82.

    Article  CAS  PubMed  Google Scholar 

  138. Guedes, P. M., Urbina, J. A., De Lana, M., Afonso, L. C., Veloso, V. M., Tafuri, W. L., Machado-Coelho, G. L., Chiari, E. & Bahia, M. T. (2004) Activity of the new triazole derivative albaconazole against Trypanosoma (Schizotrypanum) cruzi in dog hosts. Antimicrob Agents Chemother, 48, 4286–92.

    Article  PubMed  CAS  Google Scholar 

  139. Capilla, J., Yustes, C., Mayayo, E., Fernandez, B., Ortoneda, M., Pastor, F. J. & Guarro, J. (2003) Efficacy of albaconazole (UR-9825) in treatment of disseminated Scedosporium prolificans infection in rabbits. Antimicrob Agents Chemother, 47, 1948–51.

    Article  CAS  PubMed  Google Scholar 

  140. Azoles (2008) (Clotrimazole, F., itraconazole, ketoconazole, miconazole, voriconazole, posaconazole). In: Antimicrobial Therapy and Vaccines. Available at: http://www.antimicrobe.org, September 2008.

  141. Zonios, D. I. & Bennett, J. E. (2008) Update on azole antifungals. Semin Respir Crit Care Med, 29, 198–210.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Infectious Diseases, The Department of Internal Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA

    George R. Thompson III

  2. Division of Infectious Diseases, The Department of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA

    Thomas F. Patterson

Authors
  1. George R. Thompson III
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Thomas F. Patterson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to George R. Thompson III .

Editor information

Editors and Affiliations

  1. Porto Alegre, Complexo Hospitalar Santa Casa de, Av. Independencia 155, Porto Alegre, 90035-075, Brazil

    Alessandro Comarú Pasqualotto

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Springer Science+Business Media B.V.

About this chapter

Cite this chapter

Thompson, G.R., Patterson, T.F. (2009). Azoles. In: Comarú Pasqualotto, A. (eds) Aspergillosis: From Diagnosis to Prevention. Springer, Dordrecht. https://doi.org/10.1007/978-90-481-2408-4_15

Download citation

Publish with us

Policies and ethics

Search

Navigation